| Literature DB >> 28987260 |
Pegah Golabi1, Haley Bush1, Zobair M Younossi2.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is recognized as a global health problem and as a common cause of chronic liver disease. Nonalcoholic steatohepatitis (NASH) carries an increased risk for development of advanced liver disease. Lifestyle modifications with diet and exercise have been the initial management recommendation. However, these changes are difficult to achieve and sustain overtime. There are pharmacologic agents being considered for treatment of NASH. Some target insulin resistance and others focus on oxidative stress, inflammation, apoptosis, and fibrosis. There is a great deal of efforts to develop therapeutic regimens for patients with NASH and NASH with significant fibrosis.Entities:
Keywords: Clinical trials; NAFLD; NASH; Nonantifibrotics; Treatment
Mesh:
Substances:
Year: 2017 PMID: 28987260 DOI: 10.1016/j.cld.2017.06.010
Source DB: PubMed Journal: Clin Liver Dis ISSN: 1089-3261 Impact factor: 6.126